(2026). Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report. Lung Cancer: Targets and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET P.L730_G731insL After Progression on Pralsetinib: A Case Report."
Lung Cancer: Targets and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET P.L730_G731insL After Progression on Pralsetinib: A Case Report."
Lung Cancer: Targets and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.